Oramed Pharmaceuticals Stock Technical Analysis
| ORMP Stock | USD 3.85 0.01 0.26% |
As of the 24th of April, Oramed Pharmaceuticals is trading near 3.85 per share. Technical analytics identify Coefficient Of Variation of 1724.51, risk adjusted performance of 0.0613, and Semi Deviation of 3.05. The analytical framework assesses directional consistency across time frames. Peer-relative positioning is derived from normalized indicator data.
Oramed Pharmaceuticals Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Oramed, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to OramedOramed |
Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 6.25 | Hold | 1 | Odds |
Research provider recommendations for Oramed Pharmaceuticals are summarized in aggregate form. The consensus mean summarizes the distribution of analyst recommendations. Sell-side analysts covering Oramed typically assign buy, hold, or sell ratings alongside 12-month price targets. Ratings are usually accompanied by a target price comparing Oramed's fair price to its market value.
Quarterly Earnings Growth 40.9% | Earnings Share 1.5 | Revenue Per Share | Quarterly Revenue Growth -100.0% | Return On Assets |
The market value of Oramed Pharmaceuticals is measured differently than book value, which reflects Oramed accounting equity. Valuation work aligns these measures into a single analytical context.
Oramed Pharmaceuticals' estimated value and market price are complementary but separate measures of worth. Oramed Pharmaceuticals' trading price represents the transaction level agreed by market participants.
What-If Analysis
What-if analysis for Oramed Pharmaceuticals is essentially a historical sensitivity test that shows how changes in the investment horizon could have altered realized return, drawdown, and timing outcomes. The analytical value is perspective: it shows whether the thesis would have remained investable across different historical windows or depended too heavily on one favorable stretch.
| 01/24/2026 |
| 04/24/2026 |
Opening a 0.00 position in Oramed Pharmaceuticals on January 24, 2026 and holding to today would record 0.00 in aggregate return. The net result is a 0.0% net return in Oramed Pharmaceuticals in aggregate over the 90 day window. Oramed Pharmaceuticals competes with or is related to Ovid Therapeutics, Context Therapeutics, Clene, Shattuck Labs, Coya Therapeutics, MacroGenics, and ImageneBio. Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of dia... More
Upside and Downside Indicators for Oramed Pharmaceuticals Summary
Upside and downside signals that contextualize Oramed Pharmaceuticals price behavior are highlighted below. The signals are presented as informational context for recent price movement.
| Downside Deviation | 3.14 | |||
| Information Ratio | 0.055 | |||
| Maximum Drawdown | 15.85 | |||
| Value At Risk | -5.14 | |||
| Potential Upside | 5.9 |
Volatility and Risk Indicators for Oramed Pharmaceuticals Overview
These indicators track Oramed Pharmaceuticals' volatility and return range dynamics. Neutral context for risk and variability is provided.| Risk Adjusted Performance | 0.0613 | |||
| Jensen Alpha | 0.1683 | |||
| Total Risk Alpha | 0.1716 | |||
| Sortino Ratio | 0.054 | |||
| Treynor Ratio | -1.44 |
Mean reversion in Oramed Pharmaceuticals' price occurs when temporary dislocations correct back toward its historical intrinsic value estimate. This tendency of Oramed Pharmaceuticals' price to converge to an average value over time is called mean reversion.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0613 | |||
| Market Risk Adjusted Performance | -1.43 | |||
| Mean Deviation | 2.31 | |||
| Semi Deviation | 3.05 | |||
| Downside Deviation | 3.14 | |||
| Coefficient Of Variation | 1724.51 | |||
| Standard Deviation | 3.08 | |||
| Variance | 9.47 | |||
| Information Ratio | 0.055 | |||
| Jensen Alpha | 0.1683 | |||
| Total Risk Alpha | 0.1716 | |||
| Sortino Ratio | 0.054 | |||
| Treynor Ratio | -1.44 | |||
| Maximum Drawdown | 15.85 | |||
| Value At Risk | -5.14 | |||
| Potential Upside | 5.9 | |||
| Downside Variance | 9.84 | |||
| Semi Variance | 9.32 | |||
| Expected Short fall | -2.29 | |||
| Skewness | 0.1092 | |||
| Kurtosis | 0.6261 |
Oramed Pharmaceuticals Backtested Returns
Oramed Pharmaceuticals continues to exhibit an unstable price behavior over the designated horizon. It records an Efficiency (Sharpe) Ratio of 0.0517, marking performance variability over 3 months. We identified twenty-nine technical indicators influencing the company's volatility profile. Please examine metrics such as Coefficient Of Variation of 1724.51, risk-adjusted performance of 0.0613, and Semi Deviation of 3.05 to validate volatility assumptions. Oramed Pharmaceuticals has a performance score of 4 on a scale of 0 to 100. The company retains a Beta of -0.12, which signifies very low measured sensitivity to broad market movements. Oramed Pharmaceuticals shows a mild inverse relationship with the market, drifting lower in rallies and holding up during downturns. Oramed Pharmaceuticals presently retains a risk of 3.0%.
Auto-correlation | 0.16 |
Very weak predictability
Comparing Oramed Pharmaceuticals's price behavior from 24th of January 2026 to 10th of March 2026 with the period from 10th of March 2026 to 24th of April 2026 produces very weak predictability. The stronger the relationship between the current interval and its lagged values, the more accurately future price behavior of Oramed Pharmaceuticals may be projected. The coefficient of 0.16 links over 16.0% of Oramed Pharmaceuticals's present price action to its own historical movements.
| Correlation Coefficient | 0.16 | |
| Spearman Rank Test | -0.08 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
This technical analysis module for Oramed Pharmaceuticals is structured around price and volume data. This information reflects recorded price and volume activity over time.
Technical Analysis
This analysis covers thirty-seven data points across the selected time horizon. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Oramed Pharmaceuticals volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Technical Analysis Methodology & Indicators
Technical analysis of Oramed Pharmaceuticals evaluates price structure, momentum, and volatility clustering. Price movements may be comparatively less responsive to macroeconomic volatility. Oramed Pharmaceuticals has a market cap of 155.31 M, ROE of 37.1%.
Reported values for Oramed Pharmaceuticals are derived from periodic company reporting and market reference feeds and standardized for analysis.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board
Oramed Pharmaceuticals Technical Indicators
Technical indicators tied to Oramed Pharmaceuticals help investors translate chart behavior into a more structured framework for entry, exit, and risk control. A disciplined technical workflow separates stronger setups from noisier price action.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0613 | |||
| Market Risk Adjusted Performance | -1.43 | |||
| Mean Deviation | 2.31 | |||
| Semi Deviation | 3.05 | |||
| Downside Deviation | 3.14 | |||
| Coefficient Of Variation | 1724.51 | |||
| Standard Deviation | 3.08 | |||
| Variance | 9.47 | |||
| Information Ratio | 0.055 | |||
| Jensen Alpha | 0.1683 | |||
| Total Risk Alpha | 0.1716 | |||
| Sortino Ratio | 0.054 | |||
| Treynor Ratio | -1.44 | |||
| Maximum Drawdown | 15.85 | |||
| Value At Risk | -5.14 | |||
| Potential Upside | 5.9 | |||
| Downside Variance | 9.84 | |||
| Semi Variance | 9.32 | |||
| Expected Short fall | -2.29 | |||
| Skewness | 0.1092 | |||
| Kurtosis | 0.6261 |
April 24, 2026 Daily Trend Indicators
Technical indicators tied to Oramed Pharmaceuticals help investors translate chart behavior into a more structured framework for entry, exit, and risk control. A disciplined technical workflow separates stronger setups from noisier price action.
| Accumulation Distribution | 1,701 | ||
| Daily Balance Of Power | 0.09 | ||
| Rate Of Daily Change | 1.00 | ||
| Day Median Price | 3.83 | ||
| Day Typical Price | 3.83 | ||
| Price Action Indicator | 0.03 |